Triptolide (PG490)

Name: Triptolide (PG490)
Brand: Selleck Chemicals
SKU: S3604
Rating: 5 (22 reviews)

For research use only.

Catalog No.S3604 Synonyms: NSC 163062

22 publications

CAS No. 38748-32-2

Triptolide (PG490, NSC 163062) is a diterpene triepoxide, immunosuppresive agent extracted from the Chinese herb Tripterygium wilfordii. It functions as a NF-κB inhibitor with dual actions by disruption of p65/CBP interaction and by reduction of p65 protein. Triptolide (PG490) abrogates the transactivation function of heat shock transcription factor 1 (HSF1). Triptolide inhibits MDM2 and induces apoptosis through a p53-independent pathway.

Selleck's Triptolide (PG490) has been cited by 22 publications

Cell, 2017, 169(2):216-228.e19

PubMed: 28388407 ( click the link to review the publication )

Life Sci, 2021, 270:119065

PubMed: 33460661 ( click the link to review the publication )

Cell Commun Signal, 2020, 18(1):30

PubMed: 32093731 ( click the link to review the publication )

J Cell Physiol, 2020, 4

PubMed: 32495392 ( click the link to review the publication )

Front Oncol, 2020, 10;10:331

PubMed: 32211337 ( click the link to review the publication )

Biomed Pharmacother, 2020, 129:110427

PubMed: 32574974 ( click the link to review the publication )

Mol Cell, 2019, 73(3):519-532

PubMed: 30554946 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1551

PubMed: 30948728 ( click the link to review the publication )

Theranostics, 2019, 9(21):6175-6190

PubMed: 31534544 ( click the link to review the publication )

Front Oncol, 2019, 9:387

PubMed: 31157167 ( click the link to review the publication )

J Med Virol, 2019, 91(8):1440-1447

PubMed: 30900754 ( click the link to review the publication )

Biomed Pharmacother, 2019, 109:1541-1546

PubMed: 30551406 ( click the link to review the publication )

J Clin Invest, 2018, 128(9):4132-4147

PubMed: 29990311 ( click the link to review the publication )

Nat Commun, 2018, 9(1):502

PubMed: 29402884 ( click the link to review the publication )

Leukemia, 2018, 32(1):111-119

PubMed: 28588253 ( click the link to review the publication )

Int J Biol Sci, 2018, 14(1):47-56

PubMed: 29483824 ( click the link to review the publication )

Life Sci, 2018, 194:150-156

PubMed: 29288766 ( click the link to review the publication )

Toxicol In Vitro, 2018, 52:94-105

PubMed: 29902661 ( click the link to review the publication )

Elife, 2017, 6e25299

PubMed: 28760200 ( click the link to review the publication )

Biomed Pharmacother, 2017, 95:771-779

PubMed: 28892788 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4965-4970

PubMed: 29085508 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31767-79

PubMed: 26397138 ( click the link to review the publication )

Purity & Quality Control

Choose Selective ADC Cytotoxin Inhibitors

Biological Activity

Description

Targets

NF-κB ^[1]
()

HSF1 ^[1]
()

Mdm2 ^[1]
()

In vitro

Triptolide is a diterpene triepoxide with potent immunosuppressive and antiinflammatory properties. Triptolide is shown to inhibit the expression of IL-2 in activated T cells at the level of purine-box/nuclear factor and NF-κB mediated transcription activation. ^[1] Triptolide inhibits the proliferation and colony formation of tumor cells at extremely low concentrations (2–10 ng/mL). Triptolide has an inhibitory activity on breast, stomach and leukemia cell line HL-60 cells. Triptolide induces apoptosis in tumor cells by blocking NF-κB activation and sensitizing tumor cells for TNF-&alpha induced programmed cell death. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
HT-29	MoPQR5l1d3SxeHnjbZR6KGGpYXnud5Q>			NUW2ZZBtS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRvMkmgZ4VtdHNuIFnDOVA:OC5yMEKx{txO	NV\Oe4VuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0O\|A5PjRpPkKxOFcxQDZ2PD;hQi=>
HCT116	MmfMR5l1d3SxeHnjbZR6KGGpYXnud5Q>			NWTEXnVlS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5MEBKSzVyPUCuNFA1P87:TR?=	NYD3TGpkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GxNlE2PDZpPkOxNVIyPTR4PD;hQi=>
SKOV3	NVnWUIlvSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeC=>		M{DiVlczKGi{cx?=	MVfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONT2[zJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVA:OC5yMEdOwG0>	NIHRNGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEizN\|U1Oyd-MkC4N\|M2PDN:L3G+
SKOV3	NX63VGt5S3m2b4TvfIlkcXS7IHHnZYlve3R?		NGr4VIg4OiCqcoO=	NWK0SZoyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0uRVkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[XO\|YYmsJGlEPTB;MD6wNFbPxE1?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN5OEewPUc,OjR\|N{i3NFk9N2F-
SKOV3	MoXWR5l1d3SxeHnjJIFkfGm4aYT5JIFo[Wmwc4S=		NWTBVYROPzJiaILz	MWTDfZRwfG:6aXOgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVS1;WN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlAxPzMQvF2=	MmntQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyMUGyNlMoRjJ6MEGxNlI{RC:jPh?=
KBM5	MnO2R5l1d3SxeHnjbZR6KGGpYXnud5Q>		MkfaO\|IhcHK\|	MlPHR5l1d3SxeHnjbZR6KGGpYXnud5QhcW2jdHnubYIuemW\|aYP0ZY51KGi3bXHuJGtDVTViY3XscJMhcGG{Yn;ybY5oKEKlcj3BZowhXDNzNVmgcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVA:OC5yMEiz{txO	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2OU[2OUc,OjBzNEm2OlU9N2F-
SKOV3	NHfx[JpEgXSxdH;4bYNqfHliYXfhbY5{fA>?			NIHpUIlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUU0:YMzDj[YxteyCkeTDTVmIh[XO\|YYmsJGlEPTB;MD6wNFnPxE1?	M2HlNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NkO3PFc1Lz5zOU[zO\|g4PDxxYU6=
MDA-MB-468	NWLwe5NFS3m2b4TvfIlkcXS7IHHnZYlve3R?			MlzVR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUS2PEBk\WyuczDifUBUWkJiYYPzZZktKEmFNUC9NE4xOc7:TR?=	Mn;NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl4M{e4O\|QoRjF7NkO3PFc1RC:jPh?=
HCT116	NUTWT\|NCS3m2b4TvfIlkcXS7IHHnZYlve3R?		NEH5Zm44OiCqcoO=	M374UWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODIQvF2=	NU\uT\|FxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm2N\|c5PzRpPkG5OlM4QDd2PD;hQi=>
SKOV3	M3zH[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1		M17QcVczKGi{cx?=	M1y4dmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMV1Z\|IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xOc7:TR?=	NFfW[Wo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOU[zO\|g4PCd-MUm2N\|c5PzR:L3G+
KBM5	MlrjR5l1d3SxeHnjbZR6KGGpYXnud5Q>		MnvGO\|IhcHK\|	MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRm02KGOnbHzzJIhiemKxcnnu[{B4cWymIIT5dIUhSmO{LVHicEBi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5MEBKSzVyPUCuNFExO87:TR?=	NGqxbZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0PVY3PSd-MkCxOFk3PjV:L3G+
Rh30	NF;xUXhEgXSxdH;4bYNqfHliYXfhbY5{fA>?		NUPmTplvPzJiaILz	NWnsRYR5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWmh\|MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODF2zszN	MmC5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl4M{e4O\|QoRjF7NkO3PFc1RC:jPh?=
A549	NILmeY1CdnSjZ3;ubZN1KGGldHn2bZR6KGG2			NFO0UXhCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IHj1cYFvKFCDUkKg[ZhxemW\|c3XkJIlvKGi3bXHuJGE2PDliY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kAz\i2OSVfSUG8uVkh{LXnu[JVk\WRiTl\rZZBx[UJiYXP0bZZifGmxbjDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVA:OC5yMUVOwG0>	M4W2SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEm1OFkzLz5{M{i5OVQ6OjxxYU6=
SGC7901	NICyWHBEgXSxdH;4bYNqfHliYXfhbY5{fA>?		MoPLO\|IhcHK\|	MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTS2M4QTBzIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xOTYQvF2=	NUm0coJpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm2N\|c5PzRpPkG5OlM4QDd2PD;hQi=>
MOLT4	M1nDWWN6fG:2b4jpZ4l1gSCjZ3HpcpN1		MnXvO\|IhcHK\|	NYDPU\|RmS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVU:OVESgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjBzN988US=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTZ\|N{i3OEc,OTl4M{e4O\|Q9N2F-
A549	M{HUWWN6fG:2b4jpZ{Bi[3Srdnn0fUBi\2GrboP0		M3zYWFczKGi{cx?=	MoPiR5l1d3SxeHnjJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlAyPzYQvF2=	M4TlU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEGxNlI{Lz5{OECxNVIzOzxxYU6=
SMMC7721	NF;uT5VEgXSxdH;4bYNqfHliYXfhbY5{fA>?		MVG3NkBpenN?	M4S4UWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNOVUN5N{KxJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMUlOwG0>	M12yelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NkO3PFc1Lz5zOU[zO\|g4PDxxYU6=
PC3	MXnDfZRwfG:6aXOgZYN1cX[rdImgZYdicW6\|dB?=		M2LwVFczKGi{cx?=	MVzDfZRwfG:6aXOgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTB;MD6wNVg{\|ryP	NIf2eZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OECxNVIzOyd-MkiwNVEzOjN:L3G+
MCF7	NIn1W4xEgXSxdH;4bYNqfHliYXfhbY5{fA>?		MlvQO\|IhcHK\|	NIDJfnBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xOToQvF2=	NXH0[2NRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm2N\|c5PzRpPkG5OlM4QDd2PD;hQi=>
A549	NF75[HREgXSxdH;4bYNqfHliYXfhbY5{fA>?			MnHqR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{whUUN3ME2wMlAyQc7:TR?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR5MEi2OEc,OjF2N{C4OlQ9N2F-
PC3	M2X4cWN6fG:2b4jpZ4l1gSCjZ3HpcpN1			NGnwOoFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[nliU2LCJIF{e2G7LDDJR\|UxRTBwMENOwG0>	Mn\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl4M{e4O\|QoRjF7NkO3PFc1RC:jPh?=
Bel7402	MmXDR5l1d3SxeHnjbZR6KGGpYXnud5Q>		NIC3R4w4OiCqcoO=	NIrwWIlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBD\Wx5NECyJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMt88US=>	Moi3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl4M{e4O\|QoRjF7NkO3PFc1RC:jPh?=
PC3	MlexRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dB?=		MmP1O\|IhcHK\|	MUDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvODMQvF2=	NF\XXYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEizN\|U1Oyd-MkC4N\|M2PDN:L3G+
PC3	MnnPR5l1d3SxeHnjbZR6KGGpYXnud5Q>		MluyO\|IhcHK\|	NGfRc\|lEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XluIFnDOVA:OC5yMt88US=>	NGPCO3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO3PFcxQSd-MkSzO\|g4ODl:L3G+
PC3	NFG2S\|hEgXSxdH;4bYNqfHliYXfhbY5{fA>?			MWLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR\|Mh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygTWM2OD1yLkCy{txO	M37qdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NE[3NVU5Lz5{NUS2O\|E2QDxxYU6=
786-O	M{nOZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1		M1PLe\|czKGi{cx?=	MonNR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gO\|g3NU9iY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAzOs7:TR?=	M2jUOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NkO3PFc1Lz5zOU[zO\|g4PDxxYU6=
A549	MVHBcpRi\2:waYP0JIFkfGm4aYT5JIF1			M3;EcmFvfGGpb37pd5Qh[WO2aY\peJkh[XRiaIXtZY4hWEGUMjDlfJBz\XO\|ZXSgbY4hcHWvYX6gRVU1QSClZXzsd{Bkd2W6cILld5NqdmdiVFHDVlEh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB{fWK\|dHHuZ4UhWC2rbnT1Z4VlKEmOLUigdJJw\HWldHnvckBjgSCHTFnTRUwhUUN3ME2wMlAzO87:TR?=	M2rPelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEm1OFkzLz5{M{i5OVQ6OjxxYU6=
MDA-MB-231	NWmzNoRnS3m2b4TvfIlkcXS7IHHnZYlve3R?		M336OFczKGi{cx?=	M3i1fWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCyOO69VQ>?	M2SyWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NkO3PFc1Lz5zOU[zO\|g4PDxxYU6=
DU145	MVXDfZRwfG:6aXPpeJkh[WejaX7zeC=>		MknEO\|IhcHK\|	M1T4ZWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xOjUQvF2=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTZ\|N{i3OEc,OTl4M{e4O\|Q9N2F-
HO8910	MVfDfZRwfG:6aXPpeJkh[WejaX7zeC=>		MmXNO\|IhcHK\|	NWTFbWkzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUE96OUGwJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMklOwG0>	NX[yc21KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm2N\|c5PzRpPkG5OlM4QDd2PD;hQi=>
HCT15	M{XWZWN6fG:2b4jpZ4l1gSCjZ3HpcpN1		M1r6RlczKGi{cx?=	NXHEZVNHS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUWgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjB{Od88US=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTZ\|N{i3OEc,OTl4M{e4O\|Q9N2F-
A549	MoTaS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6=			MmjuS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gRVU1QSClZXzsd{whUUN3ME2wMlA{\|ryP	M{\D[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEG0N\|c1Lz5{OEixOFM4PDxxYU6=
32D	NVu1UZlGS3m2b4TvfIlkcXS7IHHnZYlve3R?		NEjXRVQ4OiCqcoO=	M3XwXmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJFMzTCClZXzsd{Bp[XKkb4Lpcochf2muZDD0fZBmKEKlcj3BZowh[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3ME2wMlA{Os7:TR?=	NInIN3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0PVY3PSd-MkCxOFk3PjV:L3G+
U251	MULDfZRwfG:6aXPpeJkh[WejaX7zeC=>			Ml7HR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWVI2OSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBjgSC\|dXzmc5Jpd2SjbXnu[UBDKGG\|c3H5MEBKSzVyPUCuNFM{\|ryP	NHGzOVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS2O\|E2QCd-MkW0OlcyPTh:L3G+
32D	M1LLWGN6fG:2b4jpZ4l1gSCjZ3HpcpN1		M1\QOlczKGi{cx?=	MnviR5l1d3SxeHnjbZR6KGGpYXnud5QhcW2jdHnubYIuemW\|aYP0ZY51KG2xdYPlJFMzTCClZXzsd{Bp[XKkb4LpcochSmO{LVHicEBVOzF3STDteZRidnRiYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiSVO1NF0xNjB\|NN88US=>	M{H2NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUS5OlY2Lz5{MEG0PVY3PTxxYU6=
PC3	MXjDfZRwfG:6aXPpeJkh[WejaX7zeC=>		MojTO\|IhcHK\|	NULNdWJnS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN\|IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xPDQQvF2=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTZ\|N{i3OEc,OTl4M{e4O\|Q9N2F-
KB	M{jqNWN6fG:2b4jpZ4l1gSCjZ3HpcpN1		MnXiO\|IhcHK\|	M2HmRWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtDKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;MD6wOFPPxE1?	NGXiPI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOU[zO\|g4PCd-MUm2N\|c5PzR:L3G+
HepG2	MYHDfZRwfG:6aXPpeJkh[WejaX7zeC=>		MknCOFghcHK\|	NVn4[G5jS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFiWVDDhd5NigSxiSVO1NF0xNjB2M{ROwG0>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODZzM{OzOUc,OzB4MUOzN\|U9N2F-
HeLa	MYLDfZRwfG:6aXPpeJkh[WejaX7zeC=>		NHjkXlc4OiCqcoO=	MlfTR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPUCuNFQ4\|ryP	NGn5THc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOU[zO\|g4PCd-MUm2N\|c5PzR:L3G+
U251	MkX2R5l1d3SxeHnjbZR6KGGpYXnud5Q>		M1\KXlczKGi{cx?=	NH;HXGdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWOjVzIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xPDoQvF2=	M1PrXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NkO3PFc1Lz5zOU[zO\|g4PDxxYU6=
K562	MYjDfZRwfG:6aXPpeJkh[WejaX7zeC=>		M37mZlczKGi{cx?=	M{X4V2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGs2PjJiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlA2\|ryP	M2XpOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NkO3PFc1Lz5zOU[zO\|g4PDxxYU6=
NIH/3T3	MmG1R5l1d3SxeHnjbZR6KGGpYXnud5Q>			MV\DfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJINmdGxidnnhZoltcXS7LDDJR\|UxRTBwMEZOwG0>	MnTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFzMkG1OFYoRjNzMUKxOVQ3RC:jPh?=
SW1116	NGTac5lEgXSxdH;4bYNqfHliYXfhbY5{fA>?		MYK3NkBpenN?	M3HyR2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNYOTFzNjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODV{zszN	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTZ\|N{i3OEc,OTl4M{e4O\|Q9N2F-
A549	M4C3bGN6fG:2b4jpZ4l1gSCjZ3HpcpN1		M3;NUlczKGi{cx?=	MnPNR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPUCuNFU6\|ryP	M3T3d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NkO3PFc1Lz5zOU[zO\|g4PDxxYU6=
HeLa	M3LUUGN6fG:2b4jpZ4l1gSCjZ3HpcpN1			M1mzWmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ4VtdCC4aXHibYxqfHluIFnDOVA:OC5yOEhOwG0>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTF{MUW0Okc,OzFzMkG1OFY9N2F-
Jurkat	NV;KXWl3S3m2b4TvfIlkcXS7IHHnZYlve3R?			NVzYVYtQS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUnW{a3H0JINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5MEBKSzVyPUCuNVTPxE1?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTF{MUW0Okc,OzFzMkG1OFY9N2F-
MKN28	NWfHfppCS3m2b4TvfIlkcXS7IHHnZYlve3R?		M2riSVczKGi{cx?=	MUnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNT24zQCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPUCuNu69VQ>?	NYTkZ45PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm2N\|c5PzRpPkG5OlM4QDd2PD;hQi=>
MDCK	MnHlR5l1d3SxeHnjbZR6KGGpYXnud5Q>			MULDfZRwfG:6aXPpeJkh[WejaX7zeEBOTEONIHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJINmdGxidnnhZoltcXS7LDDJR\|UxRTFwMt88US=>	NXLZOZp1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GxNlE2PDZpPkOxNVIyPTR4PD;hQi=>
Pkd1-/-	NXf4VpNMUW6mdXP0bY9vKG:o			MWrJcoR2[3Srb36gc4Yh[2WubDDndo94fGhiYYLy[ZN1KGmwIH3veZNmKFCtZEGtM{0h[2WubIOgbY4heHKnc3XuZ4Uhd2ZiY3HsZ4l2dQ>?	MojhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|NkC1N\|QoRjF5M{[wOVM1RC:jPh?=
Pkd1-/-	M1nHXmlv[3KnYYPlJIlv	NHn2NFEyODBibl2=	NVLpTJpkQTZiaILz	NHy2[VhKdmO{ZXHz[UBqdiCyMkHDTXAwX0GIIHX4dJJme3Orb36gbY4hdW:3c3WgVItlOS1xLTDj[YxteyCjdDCxNFAhdk1iYX\0[ZIhQTZiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN4MEWzOEc,OTd\|NkC1N\|Q9N2F-
Pkd1+/-	M1nZWWlv[3KnYYPlJIlv	NUXONYp{OTByIH7N		NHXwTXRKdmO{ZXHz[UBqdiCSQ{Kg[IVx\W6mZX70JINidGOrdX2gdoVt\WG\|ZTDpckBud3W\|ZTDQb4QyMy9vIHPlcIx{KGG2IEGwNEBvVQ>?	NYLMdJd3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezOlA2OzRpPkG3N\|YxPTN2PD;hQi=>
Pkd1-/-	MlH4TY5kemWjc3WgbY4>	NYPXR\|BQOTByIH7N		MUjJcoNz\WG\|ZTDpckBRSzJiZHXw[Y5l\W62IHPhcINqfW1icnXs[YF{\SCrbjDtc5V{\SCSa3SxMU8uKGOnbHzzJIF1KDFyMDDuUS=>	NWXmc21VRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezOlA2OzRpPkG3N\|YxPTN2PD;hQi=>
Pkd1-/-	NF7NbGJKdmO{ZXHz[UBqdg>?	MkHhOVAhfU1?		MkD3TY5kemWjc3WgbY4h[2GuY3n1cUBz\WynYYPlJIlvKG2xdYPlJHBs\DFvLz2gZ4VtdHNiYYSgOVAhfU1iaX6gdJJme2WwY3Wgc4YhWnmUIHHueIFod26rc4Sg[IFvfHKxbHXu[S=>	NFvsd5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{O2NFU{PCd-MUezOlA2OzR:L3G+
Pkd2+/-	M2fnTGdzd3e2aDDpcohq[mm2aX;uJI9nKFCFMjDlfJBz\XO\|aX7nJI1wfXOn	NFLVOnQyODBibl2=	MWWyOEBpenN?	Mn3MS5Jwf3SqIHnubIljcXSrb36gc4YhWEN{IHX4dJJme3OrbnegcY92e2ViUHvkNkswNSClZXzsd{BieyClZXzsJIRm[XSqIHH0JFExOCCwTTDh[pRmeiB{NDDodpM>	MoL1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|NkC1N\|QoRjF5M{[wOVM1RC:jPh?=
KBM5	NEnYO2REgXSxdH;4bYNqfHliYXfhbY5{fA>?	NG\MSoIxNjByMTD0c{AyPyC3TR?=	MoHzO\|IhcHK\|	NFrvOGREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMSk13IHPlcIx{KGijcnLvdolv\yC5aXzkJJR6eGViQnPyMWFjdCCjdDCwMlAxOSC2bzCxO{B2VSCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6	NILEd2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0PVY3PSd-MkCxOFk3PjV:L3G+
KBM5	M1L0Z2N6fG:2b4jpZ4l1gSCjZ3HpcpN1	NUjtXGc4OC5yMEGgeI8hOTdidV2=	NHrWPZE4OiCqcoO=	M3fFSmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGmvYYTpcoljNXKnc3nzeIFvfCCqdX3hckBMSk13IHPlcIx{KGijcnLvdolv\yCEY4KtRYJtKFR\|MUXJJI12fGGwdDDheEAxNjByMTD0c{AyPyC3TTDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7	NHnjXXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0PVY3PSd-MkCxOFk3PjV:L3G+
LNCAP	M4DzZmFvfGGpb37pd5Qh[WO2aY\peJkh[XR?	NV3BNJROPSC3TR?=	NETmOmgzPCCqcoO=	MYDBcpRi\2:waYP0JIFkfGm4aYT5JIF1KEGUIHnuJIh2dWGwIFzOR2FRKGOnbHzzJIF{e2W\|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJGRJXC2rbnT1Z4VlKHKnY3XweI9zKHS{YX7zZ5JqeHSrb37hcEBi[3Srdnn0fUBifCB3IIXNJIFnfGW{IEK0JIhzeyCkeTDkeYFtKGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeR?=	MmTMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N\|EoRjJ5OUm0O\|MyRC:jPh?=
LNCAP	MX7BcpRi\2:waYP0JIFkfGm4aYT5JIF1	M4C5R\|UxOCCwTR?=	M1\STlI1KGi{cx?=	MXvBcpRi\2:waYP0JIFkfGm4aYT5JIF1KEGUIHnuJIh2dWGwIFzOR2FRKGOnbHzzJIF{e2W\|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJGRJXC2rbnT1Z4VlKHKnY3XweI9zKHS{YX7zZ5JqeHSrb37hcEBi[3Srdnn0fUBifCB3MECgcm0h[W[2ZYKgNlQhcHK\|IHL5JIR2[WxibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5	NH\SOlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OFc{OSd-Mke5PVQ4OzF:L3G+
HepG2	MX;BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dB?=	MoXPNE4zKG2pL3vn	MUSxOUBl[Xm\|	M4\3cWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldGczKGOnbHzzJJhmdm:pcnHmeIVlKGmwIFLhcIIw[yCwdXTlJI1wfXOnIHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiC2dX3vdkBoem:5dHigZZQhOC5{IH3nM4toNCCrcDDh[I1qdmm\|dHXy[YQhd26lZTDkZYltgSCob4KgNVUh\GG7cx?=	M3LpOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNkGzN\|M2Lz5\|ME[xN\|M{PTxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	c-Jun; PubMed: 22666381 PLoS One (C) and (D) Triptolide decreased c-Jun protein level in LNCaP (C) and PC-3 (D) cells in a dose-dependent manner. Cells were treated with indicated dose of Triptolide or Celastrol for 24 h before Western blot analysis. α-tubulin was used as a loading control. MDM2; PubMed: 27004407 Oncotarget Western blot assays showing the dose-response and time-course of MDM2 inhibition by triptolide. GAPDH served as an internal control for equal protein loading. p-AKT / AKT / p-Foxo3a / Foxo3a / p53 ; PubMed: 27004407 Oncotarget Western blot assays showing the inhibitory effect of triptolide on Akt activity. MCF-7 and MDA-MB-468 cells were treated with 50 nM triptolide for different times. Cell extracts were tested by Western blot assay for the expression of MDM2, p53, p21, PUMA, Akt, phosphorylated Akt (S473), Foxo3a and phosphorylated Foxo3a. Phosphorylated Akt and phosphorylated Foxo3a were dramatically decreased following treatment with triptolide. The quantification results are shown on the graphs to the right. p-PI3K / PI3K / p85 / p110 ; PubMed: 27004407 Oncotarget Triptolide up-regulates p85 expression. MDA-MB-468 cells were treated with 50 nM triptolide for different times. Cell extracts were tested by Western blot assay for the expression of PI3K, phosphorylated PI3K, p85, p110 and REST.	22666381 27004407
Growth inhibition assay	Cell viability; PubMed: 22666381 PLoS One (C) Effect of Triptolide on LNCaP cells. (E) Effect of Triptolide on PC-3 cells.	22666381

In vivo

Triptolide synergizes with cyclosporin A in promoting graft survival in animal models and in suppression of graft versus host disease in allogeneic bone marrow transplants. In addition, it induces apoptosis in tumor cells and potentiates tumor necrosis factor (TNF-α) induction of apoptosis in part through the suppression of c-IAP2 and c-IAP1 induction. ^[1] ^[3] Triptolide treatment for 2–3 weeks inhibits the growth of xenografts formed by four different tumor cell lines (B16 melanoma, MDA-435 breast cancer, TSU bladder cancer, and MGC80-3 gastric carcinoma), indicating that TPL has a broad spectrum of activity against tumors that contain both wild-type and mutant forms of p53. In addition, Triptolide inhibits experimental metastasis of B16F10 cells to the lungs and spleens of mice. ^[2] Triptolide has in vitro and in vivo activities against mouse models of polycystic kidney disease. ^[4] LD50: Mice 0.83mg/kg (i.v.). ^[5]

Protocol

References

- Collapse

Solubility (25°C)

In vitro	DMSO	72 mg/mL warmed (199.77 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Triptolide (PG490) SDF

Molecular Weight	360.4
Formula	C₂₀H₂₄O₆
CAS No.	38748-32-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	NSC 163062
Smiles	CC(C)C12C(O1)C3C4(O3)C5(CCC6=C(C5CC7C4(C2O)O7)COC6=O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Choose Your Country or Region

By Signaling Pathways

By product type

Triptolide (PG490)